MiR-130a-3p exerts an anti-inflammatory and anti-fibrotic effect in BLM-induced PF by suppressing the proinflammatory factor TNF-α and profibrogenic activity of TGF-β1 signaling, implying an underlying therapeutic agent in the therapy of PF patients. Here, TGFB1 is linked to pemphigus foliaceus.